Q-omics provides the consensus-scored ZW10 profile across patient tissues and cancer cell-line models. ZW10 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZW10 is differentially expressed in 13, with the highest sampling consensus in BLCA. Additionally, ZW10 protein abundance shows 19,792 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, BLCA, and LUAD as cancer lineages where ZW10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZW10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZW10 survival associations across molecular data types. ZW10 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZW10 RNA expression–survival associations across cancer types. High ZW10 expression shows unfavorable associations in MESO, ACC, LIHC and LGG, but favorable associations in KIRC and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZW10 RNA expression.
This table summarizes ZW10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 8. The strongest signals are observed in HNSC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for ZW10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZW10 shows higher tumor expression in BLCA, HNSC, LIHC, STAD, COAD and LUAD. The BLCA box plot shows higher ZW10 RNA expression in tumor versus normal tissue (log2 FC = +0.525, t-test p < 0.001).
This table shows molecular features associated with ZW10 in patient tissues and cancer cell lines. In patient samples, ZW10 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ZW10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
